🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Essen
Clinical trial register · Germany

Clinical Trials in Essen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca57 Novartis Pharmaceuticals50 Eli Lilly and Company30 Amgen27 University Hospital, Essen27
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Essen

760 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
NCT05197192Chronic Lymphocytic Leukemia
DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab
German CLL Study Group
Phase 3
202
Bad Saarow, Berlin, Bremen, Cologne, Dortmund, Düsseldorf, Eschweiler, Essen
2022-04-19
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613Prostate Cancer Metastatic
DrugDarolutamide
UNICANCER
Phase 3
300
Essen
2022-04-19
Recruiting
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
DrugsBezuclastinib·Sunitinib·Midazolam
Cogent Biosciences, Inc.
Phase 3
482
Bad Saarow, Berlin, Essen, Hamburg, Hanover, Mannheim
2022-04-14
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
DrugFinerenone
Bayer
Phase 3
219
Heidelberg, Hanover, Bonn, Essen, Münster, Berlin, Hamburg
2022-03-28
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Würzburg, Mainz, Leipzig, Kiel, Berlin, Chemnitz, Essen, München
2022-03-25
Active, closed
Prostate Imaging Using MRI +/- Contrast Enhancement
NCT04571840Prostate Cancer
University College, London
Not applicable
500
Düsseldorf, Essen, Frankfurt, Hamburg
2022-03-22
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Singen, Tübingen, Munich, Aachen, Bonn, Düsseldorf, Essen, Münster
2022-03-15
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsZanubrutinib·Obinutuzumab·Lenalidomide·Rituximab
BeOne Medicines
Phase 3
799
Essen, Ulm
2022-03-10
Active, closed
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT05280470Extensive-stage Small-cell Lung Cancer
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 2
187
Berlin, Essen
2022-03-09
Recruiting
TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
NCT05462457Breast Cancer, Node-positive Breast Cancer
Kliniken Essen-Mitte
Observational
150
Essen
2022-03-07
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide
Janssen Research & Development, LLC
Phase 2
151
Berlin, Essen, Heidelberg
2022-03-01
Active, closed
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
NCT04575961Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsKeytruda·Pembrolizumab
North Eastern German Society of Gynaecological Oncology
Phase 2
33
Berlin, Essen
2022-02-22
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
DrugsDomvanalimab·Durvalumab
AstraZeneca
Phase 3
791
Berlin, Berlin-Zehlendorf, Braunschweig, Chemnitz, Cologne, Erlangen, Essen, Giessen
2022-02-18
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 2/3
286
Essen, Regensburg
2022-02-11
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Erfurt, Erlangen, Essen, Esslingen am Neckar, Georgsmarienhütte, Gütersloh, Hanover, Oldenburg
2022-02-07
Active, closed
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790Spinal Muscular Atrophy
DrugNusinersen
Biogen
Phase 3
45
Heidelberg, Ulm, Munich, Essen
2022-01-21
Active, closed
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment
NCT04999423Intracranial Aneurysm
Microvention-Terumo, Inc.
Observational
206
Augsburg, Bochum, Essen, Münster
2022-01-14
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
DrugABL001
Novartis Pharmaceuticals
Phase 1/2
34
Erlangen, Essen, Hamburg
2021-12-27
Active, closed
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226Neuroendocrine Tumors
DrugsFOLFOX (Folinic acid·Everolimus·Fluorouracil·Oxaliplatin
ITM Solucin GmbH
Phase 3
259
Berlin, Bonn, Erlangen, Essen
2021-12-21
Active, closed
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735Breast Cancer
DrugsAlpelisib·Fulvestrant
Novartis Pharmaceuticals
Phase 3
210
Cologne, Augsburg, Berlin, Essen, Lübeck
2021-12-17
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
288
München, Essen, Münster, Leipzig, Berlin, Jena
2021-12-14
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Opdivo
Exelixis
Phase 1
1,394
Essen, Hamburg, Heidelberg, Herne, Jena, München, Nürtingen, Trier
2021-12-14
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Freiburg im Breisgau, Essen, Hamburg
2021-12-13
Active, closed
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
NCT05118724Colorectal Cancer
DrugsTecentriq·Atezolizumab
AIO-Studien-gGmbH
Phase 2
80
Essen
2021-12-10
Active, closed
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)
DrugRilzabrutinib
Sanofi
Phase 2
22
Essen
2021-12-07
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
258
Berlin, Essen, Leipzig
2021-11-30
Active, closed
Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction
NCT03849586Erectile Dysfunction
European Association of Urology Research Foundation
Observational
1,076
Essen, Lübeck
2021-11-19
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Recruiting
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
NCT05281406NSCLC Stage IIIB, NSCLC Stage IV
DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin
Goethe University
Phase 2
50
Berlin, Cologne, Dresden, Essen, Frankfurt, Gauting, Georgsmarienhütte, Göttingen
2021-11-12
Recruiting
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894Generalized Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 2/3
12
Berlin, Essen
2021-10-26
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04861259Atypical Hemolytic Uremic Syndrome
DrugCrovalimab
Hoffmann-La Roche
Phase 3
83
Cologne, Essen, Hanover
2021-10-22
Active, closed
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor
DrugsCAM2029·Octreotide LAR
Camurus AB
Phase 3
332
Berlin, Erlangen, Essen, Hamburg, Heidelberg, Mannheim, Ulm
2021-10-22
Active, closed
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372Mesothelioma
Novartis Pharmaceuticals
Phase 1
137
Essen
2021-10-21
Active, closed
Low-dose Atropine for Myopia Control in Children
NCT03865160Myopia, Progressive
DrugAtropine eye
University Eye Hospital, Freiburg
Phase 2/3
302
Ahaus, Bonn, Cologne, Erlangen, Essen, Freiburg im Breisgau, Göttingen, Hamburg
2021-10-19
Active, closed
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 3
123
Berlin, Essen
2021-10-14
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
587
Dresden, Düsseldorf, Essen, Freiburg im Breisgau, Hamburg, Hamm, Heidelberg, Kiel
2021-10-14
Active, closed
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
DrugsMirvetuximab Soravtansine·Pegylated liposomal doxorubicin·Gemcitabine·Paclitaxel
AGO Research GmbH
Phase 2
136
Berlin, Dessau, Dresden, Essen, Frankfurt, Hamburg, Hanover, Karlsruhe
2021-10-13
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Cologne, Berlin, Essen, Freiburg im Breisgau
2021-10-11
Active, closed
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342Ovarian Cancer
DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib
Hoffmann-La Roche
Phase 2
176
Essen, Mannheim
2021-10-07
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Ludwigsburg, Donauwörth, Erlangen, München, Frankfurt am Main, Hanover, Essen, Mönchengladbach
2021-10-04
Recruiting
Safe and Timely Antithrombotic Removal (STAR) Registry
NCT05077124Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
CytoSorbents, Inc
Observational
1,000
Coswig, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Kiel, Leipzig
2021-09-30
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Venclyxto
Loxo Oncology, Inc.
Phase 3
600
Chemnitz, Essen, Kerpener, Koelner Platz 1, Leipzig, Rostock, Würzburg
2021-09-20
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
448
Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Kiel, Magdeburg
2021-09-20
Active, closed
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
NCT04537377Wilson's Disease
Vivet Therapeutics SAS
Phase 1/2
4
Essen, Tübingen
2021-09-03
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Karlsruhe, Augsburg, Berlin, Chemnitz, Erlangen, Essen, Georgsmarienhütte, Hamburg
2021-08-27
Recruiting
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH
Phase 2
213
Augsburg, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig
2021-08-18
Recruiting
Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
NCT04629833Steroid-refractory Acute Graft-versus-host Disease
DrugMC0518
medac GmbH
Phase 3
210
Munich, Würzburg, Frankfurt am Main, Hanover, Cologne, Essen, Münster, Dresden
2021-08-16
Active, closed
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
DrugsChidamide·Nivolumab
HUYABIO International, LLC.
Phase 3
450
Berlin, Cologne, Dresden, Erfurt, Essen, Freiburg im Breisgau, Heidelberg, Leipzig
2021-08-12
Active, closed
BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions
NCT04830228Peripheral Artery Disease
Biotronik AG
Observational
160
Bayreuth, Essen, Flensburg, Jena, Münster, Tübingen
2021-08-10
Active, closed
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
NCT04733118Early Breast Cancer
MedSIR
Phase 2
393
Cologne, Duisburg, Essen, Manheim, Potsdam
2021-08-05
Active, closed
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
DrugsTedopi·Keytruda·Pembrolizumab
ARCAGY/ GINECO GROUP
Phase 2
180
Dresden, Essen, Leipzig, Mainz, Mannheim, Ulm
2021-08-05
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Cologne, Aachen, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Mainz
2021-07-28
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
208
Dresden, Aachen, Essen, Hamburg, Riesa, Ulm
2021-07-27
Recruiting
German Cardiac Arrest Registry
NCT05142124Out-of-hospital Cardiac Arrest
Leipzig Heart Science gGmbH
Observational
400
Berlin, Bad Friedrichshall, Bonn, Bremen, Cologne, Dresden, Düsseldorf, Essen
2021-07-21
Recruiting
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
NCT04877288Renal Allograft Recipients
DrugsCyclosporine A·Belatacept·Mycophenolate Mofetil·Tacrolimus
Bristol-Myers Squibb
Phase 3
102
Essen, Cologne, Hamburg, Heidelberg
2021-07-21
Recruiting
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
NCT04284839Bleeding Post Cardiac Surgery, Indication for Anticoagulation
DrugsDOAC·Dabigatran·Edoxaban·Warfarin
Population Health Research Institute
Phase 3
3,500
Leipzig, Jena, Bonn, Essen, Hamburg
2021-07-18
Active, closed
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
NCT05043103Advanced Parkinson Disease
Britannia Pharmaceuticals Ltd.
Observational
312
Bad Segeberg, Beelitz-Heilstätten, Berlin, Cologne, Coppenbrügge, Essen, Freiburg im Breisgau, Göttingen
2021-07-06
Active, closed
Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction
NCT04844931ST Elevation Myocardial Infarction
Helios Health Institute GmbH
Not applicable
250
Bremen, Dresden, Düsseldorf, Essen, Hamburg, Leipzig, Ludwigshafen, Lübeck
2021-07-05
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib
AstraZeneca
Phase 3
315
Ansbach, Augsburg, Bonn, Chemnitz, Dresden, Erlangen, Essen, Freiburg im Breisgau
2021-06-30
Recruiting
CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting
NCT05002543Cardiac Valve Disease
Corcym S.r.l
Observational
2,150
Augsburg, Bad Nauheim, Berlin, Dresden, Essen, Magdeburg, Nuremberg, Oldenburg
2021-06-29
Active, closed
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755Neoplasms, Breast
DrugNiraparib
GlaxoSmithKline
Phase 3
40
Berlin, Cologne, Erlangen, Essen, Mannheim, München, Ulm
2021-06-28
Active, closed
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
NCT04895722Colorectal Cancer
DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab
Merck Sharp & Dohme LLC
Phase 2
302
Munich, Marburg, Essen, Dresden, Magdeburg, Berlin, Hamburg
2021-06-25
Active, closed
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761Breast Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 3
506
Berlin, Dresden, Erlangen, Essen, Frankfurt, Hamburg, Hanover, Kiel
2021-06-22
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
342
Erlangen, Bonn, Düsseldorf, Essen, Dresden, Berlin
2021-06-18
By invitation
Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
NCT04451044Coronary Artery Disease, Ischemic Heart Disease
Philips Clinical & Medical Affairs Global
Not applicable
3,212
Berlin, Erlangen, Essen, Freiburg im Breisgau
2021-06-17
Active, closed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828Prostatic Neoplasms
DrugsARDT·Illuccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
469
Essen, München
2021-06-15
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
DrugsARDT·Illuccix·Lu-PSMA
Novartis Pharmaceuticals
Phase 3
1,140
Würzburg, Cologne, Essen, München, Münster, Rostock
2021-06-09
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 1/2
1,109
Ulm, Dresden, Essen, Frankfurt, Würzburg
2021-05-27
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel
Daiichi Sankyo
Phase 3
490
Berlin, Dresden Sachsen, Essen, Frankfurt Am Main Hessen, Hamburg, Kln Nordrhein-westfalen, Leipzig
2021-05-21
Active, closed
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
NCT04544293Autoimmune Pulmonary Alveolar Proteinosis
DrugMolgramostim
Savara Inc.
Phase 3
164
Heidelberg, Muenchen-Gauting, Essen
2021-05-19
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Augsburg, Bad Krozingen, Berlin, Bremen, Bruchsal, Cologne, Dresden, Essen
2021-05-15
Active, closed
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer
DrugsCapivasertib·Ribociclib·Abemaciclib·Palbociclib
AstraZeneca
Phase 3
893
Augsburg, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Georgsmarienhütte, Hanover
2021-05-10
By invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)
DrugAficamten
Cytokinetics
Phase 2/3
900
Berlin, Essen, Goettigen, Heidelberg, Jena, Würzburg
2021-05-06
Active, closed
Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19
NCT04547257COVID-19
ExThera Medical Corporation
Not applicable
42
Aschaffenburg, Berlin, Essen
2021-05-04
Active, closed
ABLATE Versus PACE: PVI or AV Node Ablation and PM Implantation for Elderly Patients With Persistent AF
NCT04906668Atrial Fibrillation
St. Josefs-Hospital Wiesbaden GmbH
Not applicable
196
Bad Nauheim, Berlin, Essen, Frankfurt, Fürth, Hagen, Hamburg, Kaiserslautern
2021-05-01
Active, closed
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
NCT04784715Breast Cancer; HER2-positive; Metastatic
DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab
AstraZeneca
Phase 3
1,157
Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2021-04-26
Active, closed
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
NCT04475926Limb-girdle Muscular Dystrophy
Sarepta Therapeutics, Inc.
Observational
205
Giessen, Essen
2021-04-22
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
DrugsTafasitamab·Lenalidomide·Rituximab
Incyte Corporation
Phase 3
654
Amberg, Berlin, Essen, Giessen, Greifswald, Landshut, Mainz, Mannheim
2021-04-15
Active, closed
Sirolimus- vs. Paclitaxel-Drug Coated Ballons in Patients With Peripheral Artery Disease
NCT04475783Peripheral Artery Disease
Jena University Hospital
Not applicable
478
Bad Krozingen, Bruchsal, Coburg, Dresden, Essen, Flensburg, Heidelberg, Immenstadt im Allgäu
2021-04-13
Recruiting
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969Peripheral Vascular Diseases
Boston Scientific Corporation
Observational
5,000
Bruchsal, Essen, München
2021-03-29
Active, closed
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007Myelofibrosis
DrugsBMS-986158·Fedratinib·Ruxolitinib
Bristol-Myers Squibb
Phase 1/2
216
Erding, Essen, Chemnitz, Halle, Lübeck
2021-03-22
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·JDQ443·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Freiburg im Breisgau, Cologne, Dresden, Essen
2021-02-24
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
DrugsAdagrasib·Taxotere·Docetaxel
Mirati Therapeutics Inc.
Phase 3
453
Bad Berka, Bonn, Cologne, Essen, Gauting, Giessen, Grohansdorf, Halle
2021-02-23
Recruiting
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
NCT04750798Arrhythmias, Cardiac
Biosense Webster, Inc.
Observational
8,000
Bad Neustadt an der Saale, Bad Oeynhausen, Bad Segeberg, Bautzen, Essen, Frankfurt, Giessen, Hamburg
2021-02-22
Active, closed
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
NCT04732871Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
1,720
Essen, Goch, Hamburg, Mainz, München, Wallerfing, Würzburg
2021-02-15
Active, closed
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
NCT04776434Peripheral Artery Disease
M.A. Med Alliance S.A.
Not applicable
723
Arnsberg, Bad Krozingen, Buchholz, Essen, Flensburg, Hamburg, Heidelberg, Langensteinbach
2021-02-08
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,370
Berlin, Dessau-RoBlau, Essen, Freiburg im Breisgau, Mönchengladbach, München, Münster, Regensburg
2021-01-28
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib
Hoffmann-La Roche
Phase 2
920
Essen, Göttingen, Heilbronn, Mönchengladbach
2021-01-18
Active, closed
Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System
NCT04614402Tricuspid Valve Insufficiency
Edwards Lifesciences
Observational
300
Tübingen, Ulm, München, Cologne, Essen, Bad Oeynhausen, Bonn, Leipzig
2021-01-15
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
DrugEpcoritamab
Genmab
Phase 3
483
Cologne, Essen, Kiel, Würzburg
2021-01-13
Recruiting
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy
NCT04746729Neoplasms
Institut National de la Santé Et de la Recherche Médicale, France
Observational
2,670
Essen
2021-01-11
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
990
Heilbronn, Ludwigsburg, Tübingen, Hanover, Bonn, Essen, Dresden, Lübeck
2021-01-10
Active, closed
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients
NCT04720326Prophylaxis Against Liver Transplant Rejection
DrugsTacrolimus Pill·Envarsus·Tacrolimus
Edward Geissler
Phase 4
268
Aachen, Berlin, Essen, Frankfurt, Hamburg, Hanover, Heidelberg, Jena
2020-12-23
Active, closed
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Biosciences
Phase 3
182
Dresden, Essen, Frankfurt, Leipzig, Munich
2020-12-16
Active, closed
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
NCT04192747Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Elixir Medical Corporation
Not applicable
445
Bad Nauheim, Bad Segeberg, Coburg, Dortmund, Erlangen, Essen, Frankfurt, Giessen
2020-12-16
Active, closed
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
NCT04522544Hepatocellular Carcinoma Non-resectable, HCC
DrugsTremelimumab·Durvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
55
Bonn, Cologne, Essen, Göttingen, Hanover, Jena, Lübeck, München
2020-12-15
Active, closed
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy
NCT04295447Prostatic Neoplasms
DrugApalutamide Tab
Universität Münster
Phase 2
190
Münster, Augsburg, Bergisch Gladbach, Cologne, Duisburg, Düsseldorf, Essen, Frankfurt
2020-12-10
Active, closed
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
NCT04725474Solid Tumor, Adult
DrugsVisugromab·Nivolumab
CatalYm GmbH
Phase 1/2
199
Essen, Frankfurt am Main, Würzburg
2020-12-09
Active, closed
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976Lung Cancer, Non-Small Cell
DrugsCobolimab·Dostarlimab·Docetaxel
GlaxoSmithKline
Phase 2/3
758
Augsburg, Bad Berka, Berlin, Bonn, Cologne, Dresden, Essen, Frankfurt
2020-12-08
Rows per page Showing 501–600 of 760
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/essen?page=6

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 760 of those studies with a site in Essen.

How many clinical trials are recruiting in Essen?

375 of the 760 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 15 have not yet opened recruitment, 361 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.